Emrelis (Telisotuzumab Vedotin)

Telisotuzumab vedotin is a medicine used to treat a type of lung cancer whose cells have a lot of a protein called c-Met. It is given as an infusion into a vein. It works like a guided missile: an antibody finds the cancer cells and delivers a drug that kills them.

Brand names:Emrelis
Medication

What people taking Emrelis (Telisotuzumab Vedotin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Emrelis (Telisotuzumab Vedotin) for Non-Small Cell Lung Cancer?

NameHow it went

About Emrelis (Telisotuzumab Vedotin)

What It's For

Telisotuzumab vedotin, sold as Emrelis, is a prescription cancer medicine for adults with non-squamous non-small cell lung cancer (NSCLC) that is locally advanced or has spread to other parts of the body. Non-squamous describes how the cancer cells look under a microscope, and it matters because different types of lung cancer are treated differently. Emrelis is meant only for tumors that make unusually large amounts of a protein called c-Met. Before it can be prescribed, a sample of the tumor must be checked with an FDA-approved test showing strong c-Met staining on at least half of the cancer cells. It is also not a first treatment: it is used after someone has already had at least one other drug treatment for the cancer, such as chemotherapy or immunotherapy. The FDA granted Emrelis accelerated approval in 2025. That means it was approved because it shrank tumors in a meaningful share of people in an early study, before larger trials could show whether it helps people live longer or better. A study comparing it with docetaxel, a standard chemotherapy, is under way to confirm its benefit, and continued approval depends on that confirmation.

How It Works

Telisotuzumab vedotin is an antibody-drug conjugate, a treatment that joins a targeted antibody to a potent cell-killing drug. The antibody part is designed to recognize c-Met, a receptor protein on the surface of cells. When it attaches to a cancer cell carrying c-Met, the cell draws the whole molecule inside. There the connecting link is cut, releasing the drug, called MMAE (monomethyl auristatin E). MMAE disrupts microtubules, the internal scaffolding a cell needs in order to divide. Without it, the cancer cell stops dividing and dies. This targeting is the reason the medicine is reserved for tumors with high c-Met levels on testing. It does not make treatment free of side effects, though; nerve, eye and lung problems are the main ones to know about.

Dosage & Administration

Emrelis is given in a clinic or hospital as an intravenous (IV) infusion that runs over about 30 minutes, once every 2 weeks. The dose is calculated from body weight, with a set maximum for people who weigh 100 kg (about 220 pounds) or more. Treatment usually continues for as long as the cancer stays under control and side effects remain manageable. If side effects develop, the care team may pause treatment, lower the dose or stop the medicine, depending on how severe they are. Someone who has had an infusion reaction is usually given medicines beforehand at later infusions, such as an antihistamine, acetaminophen and a steroid, to make another reaction less likely.

Side Effects

Nerve damage in the hands and feet, called peripheral neuropathy, is the most common side effect. In the main study, about half of people developed it, typically after a few months of treatment, and it was the most frequent reason for lowering the dose or stopping. It can feel like numbness, tingling, burning or pain, and it sometimes causes muscle weakness. Mention new or worsening symptoms at the next contact with the care team rather than waiting, since the dose is adjusted according to severity. In the study, weakness from nerve damage often had not resolved a month after the last dose. Tiredness, lower appetite and swelling of the legs, feet or hands each affected roughly a quarter of people. Nausea, constipation and vomiting were less common. Problems on the surface of the eye affected about a quarter of people, most often blurred vision, inflammation of the clear front layer of the eye (keratitis) and dry eye. Tell the care team about vision changes or other eye problems; an eye specialist may need to examine the eyes, and treatment may be paused. The most serious risk is inflammation of the lungs, called interstitial lung disease or pneumonitis. It affected about 1 in 10 people in the study, usually within the first three months, and some cases were fatal. Contact the care team right away for a new or worsening cough, shortness of breath or fever. Pneumonia, a lung infection, was also among the more frequent serious problems. Infusion reactions are uncommon. Fever, chills, rash, flushing, chest discomfort or trouble breathing during or after an infusion should be reported to the care team immediately.

Interactions & Warnings

Emrelis can harm a developing baby. Anyone who could become pregnant has a pregnancy test before starting. Women who could become pregnant should use effective birth control during treatment and for 2 months after the last dose, and men whose partners could become pregnant should use it for 4 months after the last dose. Breastfeeding is not recommended during treatment or for 1 month afterward. The medicine may also reduce fertility in both women and men, which is worth raising before treatment starts if future children matter. Emrelis is generally avoided in people with moderate or severe liver impairment, because they are likely to have higher levels of MMAE in the body and a greater risk of side effects. Some medicines strongly block CYP3A, a liver enzyme the body uses to process many drugs. Examples include the antibiotic clarithromycin and the antifungals itraconazole and ketoconazole. Taking one of these with Emrelis can raise MMAE levels, so the care team will watch more closely for side effects. Share a full list of prescriptions, over-the-counter medicines and supplements before starting.

What to Expect

Treatment means a clinic visit every 2 weeks. At these visits the team asks about nerve, eye and breathing symptoms, and blood tests track liver function, blood sugar, blood cell counts and minerals, which shifted in many people in the study. Regular scans show whether the cancer is shrinking, stable or growing. Results vary. In the study that supported approval, about 1 in 3 people (35%) had their tumors shrink substantially, and none had the cancer disappear completely. Among those who responded, the response lasted a median of about 7 months, and about 1 in 5 were still responding at a year. Because that study did not compare Emrelis with another treatment, it is not yet known whether it helps people live longer than standard options. About 3 in 10 people in the study stopped Emrelis because of side effects, and many more needed a pause or a lower dose. Reporting symptoms early lets the team adjust the dose to their severity, which is how many people are able to keep going with treatment.

Questions to Ask Your Doctor

  1. 1.Has my tumor been tested for c-Met with an approved test, and what did the result show?
  2. 2.How does Emrelis compare with my other options, such as docetaxel or a clinical trial?
  3. 3.Who should I call if I notice numbness, vision changes or a new cough between infusions?
  4. 4.How will we judge whether it is working, and how often will I have scans?
  5. 5.What do I need to plan for around birth control, fertility or breastfeeding during treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.